Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme (2011)

Peer-Reviewed Study · Bai RY; Staedtke V; Aprhys CM; Gallia GL; Riggins GJ · July 15, 2011

Bai RY et al., 2011-07-15: The Johns Hopkins paper that states the accidental origin of the benzimidazole-brain-tumour finding: fenbendazole blocked tumour engraftment, and follow-up testing identified mebendazole as the better candidate, extending survival up to 63% in orthotopic mouse glioma models. It is the direct source of the 'accidental finding' narrative.

During routine animal studies, we serendipitously observed that fenbendazole, a benzimidazole antihelminthic used to treat pinworm infection, inhibited brain tumor engraftment. Subsequent in vitro and in vivo experiments with benzimidazoles identified mebendazole as the more promising drug for GBM therapy.

abstract

Bai RY et al., 2011-07-15: The Johns Hopkins paper that states the accidental origin of the benzimidazole-brain-tumour finding: fenbendazole blocked tumour engraftment, and follow-up testing identified mebendazole as the better candidate, extending survival up to 63% in orthotopic mouse glioma models. It is the direct source of the 'accidental finding' narrative. Study type: preclinical, cell lines plus syngeneic and xenograft orthotopic mouse glioma models. N: in vivo cohort sizes in full text (not read – PMC full text blocked by a reCAPTCHA wall on the access date; Neuro-Oncology full text paywalled). Country: United States (Johns Hopkins). Dose: described in the abstract only as 'doses documented as safe in humans'; the 2015 follow-up (MBA-35) gives 50 mg/kg/day oral gavage. Funder/conflicts: not readable from the abstract or an accessible full text; the group's 2015 paper discloses a Johns Hopkins patent application. Comparator: untreated/vehicle mice. The word 'serendipitously' is the authors' own, and is what grounds the claim's 'accidental finding'. Also filed as MBB-35 (claims C5, C7).